CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01931787 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Small Cell Lung Cancer

Interventions

DRUG: 6,8-bis(benzylthio)octanoic acid

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]